跳到正文
原文
Nature Medicine· Jia Xu·· 2026-10-06AI 评分23

体内 BCMA CAR-T 治疗复发/难治性多发性骨髓瘤的延长随访

Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma

AI 导读

4例复发/难治性多发性骨髓瘤患者接受体内 BCMA CAR-T 细胞治疗后,延长随访显示3例缓解持续时间有限,1例持续缓解至15个月。研究发表于 Nature Medicine。

正文

Nature Medicine, Published online: 06 October 2026; doi:10.1038/s41591-026-04704-z

Extended follow-up of four patients with multiple myeloma treated with in vivo BCMA CAR-T cells showed limited duration of response in three patients, while one patient had sustained response to 15 months.

来源:Nature Medicine · nature.com